Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN